Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, San Francisco
Canadian Cancer Trials Group
Corcept Therapeutics
Cancer Trials Ireland
Danish Gynecological Cancer Group
National Cancer Institute (NCI)
Medical College of Wisconsin
Hoffmann-La Roche
National Cancer Institute, Naples
Jazz Pharmaceuticals
University of Florida
Bayer
Seagen Inc.
Centre hospitalier de l'Université de Montréal (CHUM)
Peking University People's Hospital
M.D. Anderson Cancer Center
3D Medicines
Memorial Sloan Kettering Cancer Center